Swiss market entry for pharmaceutical companies
Switzerland is a small, wealthy, tightly regulated market that is not covered by any EU authorisation. This is what it takes to enter it: the numbers that justify the effort, the legal steps in order, and the traps that cost a launch year.
Is the Swiss market worth entering?
For most specialty and orphan products, yes. Switzerland has roughly nine million inhabitants, universal compulsory health insurance, high per capita health spending and a medicines market of the order of CHF 7 billion at ex-factory prices. Per patient it is one of the most valuable markets in Europe, and a reimbursed Swiss price also feeds international price comparisons elsewhere.
The counterweight is fixed cost: a separate authorisation, three language versions of everything, a Swiss holder, a Swiss safety function and a separate reimbursement procedure. The decision is therefore rarely about the market and almost always about how cheaply you can build the local operation.
| Figure | Value | Why it matters |
|---|---|---|
| Population | About 9 million | Small volumes, high value per patient |
| National languages | Four, three mandatory on packs | Product information in German, French and Italian |
| Medicines market | Order of CHF 7bn ex-factory | Interpharma industry figures |
| Health insurance | Compulsory for all residents | Reimbursement decides real access |
| Reimbursement list | Spezialitätenliste at the FOPH | Separate procedure after authorisation |
| Authorisation validity | Five years, renewable | Ongoing maintenance duty |
| Regulator | Swissmedic, Bern | National authority, not the EMA |
Why an EU authorisation is not enough
Switzerland is neither an EU nor an EEA member, so neither a centralised EMA authorisation nor a national EU authorisation is valid here. Every medicine needs its own Swissmedic authorisation, held by a company with a Swiss domicile under Art. 10 HMG. Art. 13 HMG does require Swissmedic to take account of a comparable foreign authority's assessment results, which shortens the work but is not recognition.
There is a mutual recognition arrangement between Switzerland and the EU for GMP inspections and batch certificates in the manufacturing area, which is why your EU manufacturing site is usually accepted. The authorisation itself, the product information and the reimbursement are Swiss.
The three permissions you need
1. Authorisation from Swissmedic for the product. 2. A holder with a Swiss domicile to own that authorisation and its duties. 3. An establishment licence for whoever imports, stores and wholesales the product in Switzerland. Missing any one of the three stops the launch.
The entry sequence, in order
The order below is the one that avoids rework. The most common sequencing error is treating reimbursement as a post-approval task: by then your European prices are set and they have already capped your Swiss price.
- Classification and procedure. Is it a medicine under the HMG, which dispensing category is realistic, which authorisation procedure fits.
- Price strategy. Model the Swiss price against your reference country prices before you finalise European pricing.
- Holder decision. Own Swiss entity or a service holder, with the full cost of an entity compared honestly.
- Dossier adaptation. Swiss forms, Swiss modules, product information and labelling in German, French and Italian.
- Submission and question handling with Swissmedic.
- Reimbursement application to the FOPH, filed as early as the procedure allows.
- Supply chain. Import and wholesale licence coverage, GDP storage, batch release, wholesaler article data.
- Launch. Artwork, first delivery, hospital and specialist channel, medical information in three languages.
What the four language regions really cost you
Product information and packaging text must be available in German, French and Italian. That is three sets of texts to write, approve, typeset, keep synchronised through every variation and reprint. It is the single most underestimated cost of Swiss entry, and it recurs with every label change rather than once.
- Three language versions of the Fachinformation and the Patienteninformation.
- Multilingual packaging that still has to fit on the pack, which often drives a Swiss-specific artwork.
- Medical information and complaint intake in at least German and French, in practice also Italian.
- Healthcare professional communication per language region, with different prescribing habits.
Distribution and the hospital channel
Retail supply runs through a small number of full-line wholesalers who expect next-day delivery and correct article master data. Hospitals buy through their own pharmacies and through purchasing groups, often on tender cycles, and for specialty products this is where the volume sits. Plan both channels, and plan the tender calendar a year ahead.
Five traps that cost a launch year
- Setting EU prices without modelling Switzerland. The international price comparison is mechanical and unforgiving.
- Filing for reimbursement after approval. You lose months of reimbursed sales you will never recover.
- Assuming an EU label travels. Swiss product information has its own structure and three languages.
- No licensed importer in place at approval. The authorisation is worthless until someone may legally import.
- A holder without a real Swiss presence. Swissmedic writes letters with deadlines, and inspectors visit addresses.
Frequently asked questions
How big is the Swiss pharmaceutical market?
The Swiss medicines market is in the order of CHF 7 billion measured at ex-factory prices, according to industry figures published by Interpharma. Retail values are higher because distribution margins and VAT come on top. For planning, use ex-factory figures, because that is the level at which your Swiss price is set and compared.
Do we need a Swiss company to enter the market?
You need a holder with a Swiss domicile, which is either your own Swiss entity or an established Swiss holder acting for you. You also need someone with a Swissmedic establishment licence to import and wholesale. Both can be outsourced to the same partner.
How long does Swiss market entry take?
From a complete EU dossier, a realistic plan is a few months of preparation, the Swissmedic procedure on top, and the reimbursement procedure partly in parallel. Products using foreign assessment results and simplified procedures are faster. The fastest route to a marketed Swiss product is always an existing authorisation, acquired and transferred.
Is Switzerland part of the EU regulatory network?
No. Switzerland is not an EU or EEA member, has its own authority, its own law and its own reimbursement system. It participates in international cooperation and work-sharing with other authorities, and there is a mutual recognition arrangement with the EU in the GMP area, but authorisation decisions are Swiss.
Can we sell to Swiss customers from an EU warehouse?
Not as a way around the rules. Placing medicines on the Swiss market requires a Swiss authorisation and licensed import and wholesale. Individual imports for a named patient exist as a narrow exception and are not a commercialisation strategy.
Enquire about Swiss MAH support
Describe your product, dossier status and support needs. Enquiries reach the website operator at info@mahswitzerland.com. Provider qualifications, availability and contracts must be checked separately.
- Independent information portal
- Public Swiss sources, independent explanations, and enquiries about external specialist services.